clorgyline has been researched along with Parkinson Disease, Secondary in 2 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, CF | 1 |
| Wang, ZZ | 1 |
| Chen, KZ | 1 |
| Xu, TF | 1 |
| Hao, GF | 1 |
| Adeyemo, OM | 1 |
| Youdim, MB | 1 |
| Markey, SP | 1 |
| Markey, CJ | 1 |
| Pollard, HB | 1 |
2 other studies available for clorgyline and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Amides; Animals; Benzylamines; Binding Sites; | 2020 |
L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Dopamine; Goldfish; Monoamine Oxidase; Motor Act | 1993 |